

AEROBES

| ORGANISM | SPECIFIC PHENOTYPE | MEDIA ⁶⁾ | INOCULUM | | SUGGESTED MIC PANEL ³⁾ | INCUBATION | | RECOMMENDED QUALITY CONTROL | | COMMENTS ⁴⁾ |
|---------------|---|---|----------------|-------------------|---|---------------------------|-------------------------|--|------------------------------|---|
| | | | McF equivalent | Suspension medium | | Time (h) | Temperature/ Atmosphere | Strain | ATCC® | |
| Staphylococci | MRSA | MHA | 0.5 | Saline | Cefoxitin (FX) | 18-24h | 35 ± 2°C Ambient air | <i>Staphylococcus aureus</i> <i>S. aureus</i> | 29213™ 43300™ | ≤ 4 mg/L > 4 mg/L |
| | | Mueller Hinton agar (MHA) + 2% NaCl | 0.5-1 | Saline | Oxacillin (OX) Amoxicillin/clavulanic acid (XL) | 24h | 35 ± 2°C Ambient air | <i>S. aureus</i> | 43300™ | - Phenotype interpretation: OX ≥ 4 µg/mL and XL ≥ 8 µg/mL - Heavier inoculum improves detection of low level R |
| | BORSA | MHA + 2% NaCl | 0.5-1 | Saline | Oxacillin (OX) Amoxicillin/clavulanic acid (XL) | 24h | 35 ± 2°C Ambient air | <i>S. aureus</i> | 29213™ | - Phenotype interpretation: OX ≥ 4 µg/mL and XL ≤ 4 µg/mL |
| | MRCNS | Mueller Hinton agar (MHA) + 2% NaCl | 0.5-1 | Saline | Oxacillin (OX) | 48h | 35 ± 2°C Ambient air | <i>S. aureus</i> | 43300™ | - Phenotype interpretation: OX ≥ 0.5 µg/mL - Heavier inoculum improves detection of low level R |
| | VISA/hVISA ¹⁾ (macromethod) | Brain Heart Infusion agar (BHI) ¹⁾ | 2 | BHI broth | Vancomycin (VA) Teicoplanin (TP) ¹⁾ | 24h. Confirm at 48h | 35 ± 2°C Ambient air | <i>S. aureus</i> QC ranges: TP = 0.5-2 µg/mL VA = 1-4 µg/mL | 29213™ | - 0.1 mL inoculum/ 90mm plate - Phenotype interpretation: VA ≥ 8µg/mL and TP ≥ 8µg/mL, OR TP ≥12 µg/mL (alone) = VISA/hVISA - Confirm VISA/hVISA by PAP |
| | VISA/hVISA | MHA + 5% blood | 0.5 | BHI broth | Etest GRD ²⁾ (Vancomycin (VA) / Teicoplanin (TP) ¹⁾) | 18-24h. Confirm at 48h | 35 ± 2°C Ambient air | <i>S. aureus</i> <i>S. aureus</i> <i>S. aureus</i> | 29213™ 700698™ 700699™ | - Confirm VISA/hVISA by PAP |
| | VISA/VRSA (standard method) | MHA | 0.5 | Saline | Vancomycin (VA) | 24h | 35 ± 2°C Ambient air | <i>S. aureus</i> | 29213™ | - Phenotype interpretation: VA ≥ 4µg/mL = VISA VA ≥ 16µg/mL = VRSA (CLSI) |

| ORGANISM | SPECIFIC PHENOTYPE | MEDIA ⁶⁾ | INOCULUM | | SUGGESTED MIC PANEL ³⁾ | INCUBATION | | RECOMMENDED QUALITY CONTROL | | COMMENTS ⁴⁾ |
|--------------------|--------------------------|---------------------|---------------------------------|-------------------|---|---|-------------------------|---|-----------------------------|--|
| | | | McF equivalent | Suspension medium | | Time (h) | Temperature/ Atmosphere | Strain | ATCC® | |
| Staphylococci | MRSA Secondary panel | MHA | 0.5 | Saline | Clindamycin (CM) Daptomycin (DPC) Linezolid (LZ) Vancomycin (VA) Teicoplanin (TP) ¹⁾ Quinupristin/dalfopristin (QDA) Rifampicin (RI) ¹⁾ | 16-20h. VA and TP full 24h | 35 ± 2°C Ambient air | <i>S. aureus</i> | 29213™ | |
| | Non-MRSA secondary panel | MHA | 0.5 | Saline | Benzylpenicillin (PG) Erythromycin (EM) Linezolid (LZ) Trimethoprim/sulfamethoxazole (TS) Vancomycin (VA) Teicoplanin (TP) ¹⁾ Ciprofloxacin (CI) | 16-20h. VA and TP full 24h | 35 ± 2°C Ambient air | <i>S. aureus</i> | 29213™ | |
| Enterococci | | MHA | 0.5 | Saline | Ampicillin (AM) Daptomycin (DPC) Linezolid (LZ) Quinupristin/dalfopristin (QDA) Vancomycin (VA) Teicoplanin (TP) ¹⁾ Minocycline (MC) | 16-20h. Confirm VA and TP at 24h | 35 ± 2°C Ambient air | <i>E. faecalis</i> | 29212™ | |
| | HLAR | MHA | 0.5-1 | Saline | Gentamicin (GM) high range Streptomycin (SM) high range ¹⁾ | 24h. Confirm SM at 48h | 35 ± 2°C Ambient air | <i>E. faecalis</i> QC ranges: GM = 4-16 µg/mL SM = 64-256 µg/mL | 29212™ | - Heavier inoculum preferable - SM > 1024 µg/mL or GM > 512 µg/mL = positive HLAR (CLSI) - SM > 512 µg/mL or GM > 128 µg/mL = positive HLAR (EUCAST) |
| Enterobacteriaceae | | MHA | 0.5 (1 for mucoid organisms) | Saline | Gentamicin (GM) Piperacillin/ tazobactam (PTc) Cefepime (PM) Ciprofloxacin (CI) Imipenem (IP) Aztreonam (AT) | 16-20h | 35 ± 2°C Ambient air | <i>Escherichia coli</i> <i>E. coli</i> | 25922™ 35218™ (PTc) | |
| | ESBL | MHA | 0.5 (1 for mucoid organisms) | Saline | Cefotaxime/cefotaxime + clavulanic acid (CT/CTL) Ceftazidime/ceftazidime + clavulanic acid (TZ/TZL) Cefepime/cefepime + clavulanic acid (PM/PML) ¹⁾ | 16-20h | 35 ± 2°C Ambient air | <i>E. coli</i> <i>Klebsiella pneumoniae</i> (ESBL positive) <i>Pseudomonas aeruginosa</i> | 35218™ 700603™ 27853™ | - Investigate ND results by an alternative method |

| ORGANISM | SPECIFIC PHENOTYPE | MEDIA ⁶⁾ | INOCULUM | | SUGGESTED MIC PANEL ³⁾ | INCUBATION | | RECOMMENDED QUALITY CONTROL | | COMMENTS ⁴⁾ |
|-------------------------------------|--------------------------|---------------------|---------------------------------|-------------------|--|---------------------------------|-------------------------|---|------------------------|---|
| | | | McF equivalent | Suspension medium | | Time (h) | Temperature/ Atmosphere | Strain | ATCC® | |
| <i>Enterobacteriaceae</i> | MBL MP/MPI ¹⁾ | MHA | 0.5 (1 for mucoid organisms) | Saline | Meropenem/Meropenem +EDTA (MP/MPI) | 16-20h. | 35 ± 2°C Ambient air | <i>K. pneumoniae</i> <i>K. pneumoniae</i> | 700603™ BAA-2146™ | - Investigate ND results by an alternative method |
| | AmpC ²⁾ | MHA | 0.5 | Saline | Cefotetan/Cefotetan + Cloxacillin (CN/CNI) | 16-20h | 35 ± 2°C Ambient air | <i>Klebsiella pneumoniae</i> (negative) <i>K. pneumoniae</i> (positive) | 700603™ BAA-1144™ | - Investigate ND results by an alternative method |
| <i>Pseudomonas</i> spp. | | MHA | 0.5 (1 for mucoid organisms) | Saline | Ceftazidime (TZ) Gentamicin (GM) Aztreonam (AT) Ciprofloxacin (CI) Imipenem (IP) Piperacillin/tazobactam (PTc) | 16-20h. 48h for slow growers | 35 ± 2°C Ambient air | <i>P. aeruginosa</i> <i>E. coli</i> | 27853™ 35218™ (PTc) | |
| | MBL IP/IPI ¹⁾ | MHA | 0.5 (1 for mucoid organisms) | Saline | Imipenem/imipenem + EDTA (IP/IPI) | 16-20h. 48h for slow growers | 35 ± 2°C Ambient air | <i>P. aeruginosa</i> (negative) <i>Stenotrophomonas maltophilia</i> (positive) | 27853™ 13636™ | - Investigate ND results by an alternative method |
| <i>Acinetobacter</i> spp. | | MHA | 0.5 (1 for mucoid organisms) | Saline | Ceftazidime (TZ) Meropenem (MP) Amikacin (AK) Ampicillin/sulbactam (AB) Levofloxacin (LE) Minocycline (MC) | 20-24h. 48h for slow growers | 35 ± 2°C Ambient air | <i>P. aeruginosa</i> <i>E. coli</i> | 27853™ 35218™ (AB) | |
| | MBL IP/IPI ¹⁾ | MHA | 0.5 (1 for mucoid organisms) | Saline | Imipenem/imipenem + EDTA (IP/IPI) | 16-20h. 48h for slow growers | 35 ± 2°C Ambient air | <i>P. aeruginosa</i> (negative) <i>Stenotrophomonas maltophilia</i> (positive) | 27853™ 13636™ | - Investigate ND results by an alternative method |
| <i>Burkholderia cepacia</i> | | MHA | 0.5 (1 for mucoid organisms) | Saline | Trimethoprim/sulfamethoxazole (TS) Ceftazidime (TZ) Levofloxacin (LE) Meropenem (MP) Minocycline (MC) | 20-24h. 48h for slow growers | 35 ± 2°C Ambient air | <i>E. coli</i> | 25922™ | |
| <i>Stenotrophomonas maltophilia</i> | | MHA | 0.5 (1 for mucoid organisms) | Saline | Trimethoprim/sulfamethoxazole (TS) Ceftazidime (TZ) Levofloxacin (LE) Minocycline (MC) Ticarcillin/clavulanic acid (TLc) | 20-24h. 48h for slow growers | 35 ± 2°C Ambient air | <i>E. coli</i> <i>E. coli</i> | 25922™ 35218™ (TLc) | |

FASTIDIOUS ORGANISMS

| ORGANISM | SPECIFIC PHENOTYPE | MEDIA ⁶⁾ | INOCULUM | | SUGGESTED MIC PANEL ³⁾ | INCUBATION | | RECOMMENDED QUALITY CONTROL | | COMMENTS ⁴⁾ |
|---|--------------------|---|---------------------------------|--|---|---|--------------------------------|--|----------------------------|--|
| | | | McF equivalent | Suspension medium | | Time (h) | Temperature/ Atmosphere | Strain | ATCC® | |
| Pneumococci | | MHA + 5% blood (CLSI) MHF (EUCAST) | 0.5 (1 for mucoid organisms) | MH broth or BHI broth | Meropenem (MP) Cefotaxime (CT) Benzylpenicillin (PG) Clindamycin (CM) ¹⁾ Vancomycin (VA) Trimethoprim/sulfamethoxazole (TS) | 20-24h | 35 ± 2°C 5% CO ₂ | <i>Streptococcus pneumoniae</i> | 49619™ | |
| Streptococci | | MHA + 5% blood (CLSI) MHF (EUCAST) | 0.5 (1 for mucoid organisms) | MH broth or BHI broth | Benzylpenicillin (PG) Cefotaxime (CT) Chloramphenicol (CL) Ofloxacin (OF) Linezolid (LZ) ¹⁾ Vancomycin (VA) Daptomycin (DPC) | 20-24h | 35 ± 2°C 5% CO ₂ | <i>S. pneumoniae</i> | 49619™ | |
| <i>Abiotrophia</i> & <i>Granulicatella</i> spp. ¹⁾ | | MH chocolate agar + 0.001% pyridoxal HCl + 0.01% cysteine | 1 | Broth (MH broth or BHI broth) | | 20-24h | 35 ± 2°C 5% CO ₂ | ⁵⁾ | ⁵⁾ | |
| <i>Haemophilus influenzae</i> | | Haemophilus Test Media (HTM) (CLSI) MHF (EUCAST) | 0.5 (1 for mucoid organisms) | MH broth or HTM broth (or BHI broth) | Amoxicillin/ clavulanic acid (XL) Cefotaxime (CT) Meropenem (MP) Trimethoprim/sulfamethoxazole (TS) Chloramphenicol (CL) | 20-24h | 35 ± 2°C 5% CO ₂ | <i>Haemophilus influenzae</i> <i>H. influenzae</i> | 49247™ 49766™ (MP, XM) | |
| <i>Moraxella catarrhalis</i> ¹⁾ | | MHA + 5% blood (CLSI) MHF (EUCAST) | 0.5 | MH broth or BHI broth | | 20-24h | 35 ± 2°C 5% CO ₂ | ⁵⁾ | ⁵⁾ | |
| Anaerobes | | Brucella agar + 5% blood + vitamin K (1 µg/mL) + hemin (5 µg/mL) (BBA) (CLSI) | 1 | Brucella broth or MH broth (or Schaedler Broth + vit K3) | Metronidazole (MZ) Clindamycin (CM) Cefoxitin (FX) Imipenem (IP) Piperacillin/tazobactam (PTc) Benzylpenicillin (PG) | 24-72h (48h for CM). Confirm all S results at 48h. | 35 ± 2°C Anaerobic system | <i>Bacteroides fragilis</i> <i>B. thetaiotaomicron</i> <i>Eubacterium lentum</i> | 25285™ 29741™ 43055™ | - For obligate anaerobes, ensure anaerobic conditions are maintained throughout processing - DO NOT VORTEX - Anaerobiosis must be achieved within 1-2 hours for MZ |

| ORGANISM | SPECIFIC PHENOTYPE | MEDIA ⁶⁾ | INOCULUM | | SUGGESTED MIC PANEL ³⁾ | INCUBATION | | RECOMMENDED QUALITY CONTROL | | COMMENTS ⁴⁾ |
|--|--------------------|--|----------------|---|--|---------------|---|--|------------------|--|
| | | | McF equivalent | Suspension medium | | Time (h) | Temperature/ Atmosphere | Strain | ATCC® | |
| <i>Helicobacter pylori</i> ¹⁾ | | MHA + 5% blood (≥ 2 weeks old) (CLSI) | 3 | MH broth + 5% serum or BHI broth + 5% serum | Amoxicillin (AC) Clarithromycin (CH) Metronidazole (MZ) Tetracycline (TC) | 72h or longer | 35 ± 2°C Micro-aerophilic, except MZ - first 24h anaerobic | <i>Helicobacter pylori</i> | 43504™ | - 1 strip/90mm plate - Strip handle to be placed at edge of plate. - <i>H. pylori</i> colonies are pin-point, translucent and difficult to see. Tilt plate and use oblique light to read endpoint. |
| Gonococci | | Supplemented GC agar (CLSI) MH chocolate agar | 0.5 | MH broth (or BHI broth) | Ciprofloxacin (CI) Benzylpenicillin (PG) Tetracycline (TC) Ceftriaxone (TX) Spectinomycin (SC) ¹⁾ | 20-24h | 35 ± 2°C 5% CO ₂ | <i>Neisseria gonorrhoeae</i> | 49226™ | - 3-4 strips max./150mm plate to facilitate reading |
| Meningococci ¹⁾ | | MHA + 5% blood (CLSI) MH chocolate agar | 0.5 | Broth (BHI broth) | Ciprofloxacin (CI) Benzylpenicillin (PG) Trimethoprim/sulfamethoxazole (TS) Meropenem (MP) Ceftriaxone (TX) | 24h | 35 ± 2°C 5% CO ₂ | <i>S. pneumoniae</i> <i>E. coli</i> | 49619™ 25922™ | - Work in BSC |
| <i>Campylobacter</i> spp. ¹⁾ | | MHA + 5% blood (CLSI) MHF (EUCAST) | 1 | Broth (BHI broth) | Ciprofloxacin (CI) Gentamicin (GM) Erythromycin (EM) Doxycycline (DC) | 48-72h | 35 ± 2°C Micro-aerophilic | <i>Campylobacter jejuni</i> | 33560™ | - 3-4 strips max./150mm plate to facilitate reading - Do not invert plate - <i>Campylobacter</i> colonies may be translucent and difficult to see. Tilt plate and use oblique light to read endpoint. |

FASTIDIOUS GRAM-POSITIVE ORGANISMS ¹⁾

| ORGANISM | SPECIFIC PHENOTYPE | MEDIA ⁶⁾ | INOCULUM | | SUGGESTED MIC PANEL ³⁾ | INCUBATION | | RECOMMENDED QUALITY CONTROL | | COMMENTS ⁴⁾ |
|---|--------------------|---|----------------|-------------------|-----------------------------------|--------------------------|--------------------------------|-----------------------------|-------|------------------------|
| | | | McF equivalent | Suspension medium | | Time (h) | Temperature/ Atmosphere | Strain | ATCC® | |
| <i>Arcanobacterium</i> spp., <i>Listeria monocytogenes</i> *, <i>Erysipelothrix</i> , <i>Lactobacillus</i> , <i>Corynebacterium</i> , <i>Bacillus</i> spp., <i>Rothia</i> , <i>Pediococcus</i> *, <i>Leuconostoc</i> *, and <i>Gemella</i> spp.* | | MHA + 5% blood (CLSI) * MHF (EUCAST) | 1 | Broth (BHI broth) | | 20-24h (48h if required) | 35 ± 2°C 5% CO ₂ | 5) | 5) | |

FASTIDIOUS GRAM-NEGATIVE ORGANISMS ¹⁾

| ORGANISM | SPECIFIC PHENOTYPE | MEDIA ⁶⁾ | INOCULUM | | SUGGESTED MIC PANEL ³⁾ | INCUBATION | | RECOMMENDED QUALITY CONTROL | | COMMENTS ⁴⁾ |
|-------------------------------|--------------------|--|----------------|---|--|------------|--|--|-----------------------|---|
| | | | McF equivalent | Suspension medium | | Time (h) | Temperature/ Atmosphere | Strain | ATCC® | |
| <i>Bartonella</i> spp. | | MH chocolate agar | 1 | Broth (BHI broth) | | 3-5 days | 35 ± 2°C 5% CO ₂ | ⁵⁾ | ⁵⁾ | |
| <i>Bordetella pertussis</i> | | Regan-Lowe Bordet-Jengou or MHA + 5% blood | 3 | Broth (BHI broth) | | 3-5 days | 35 ± 2°C Ambient air in bags, moist | ⁵⁾ | ⁵⁾ | |
| <i>Capnocytophaga</i> spp. | | BBA | 1 | Broth (BHI broth) | | 48h | 35 ± 2°C 5% CO ₂ | ⁵⁾ | ⁵⁾ | |
| <i>Legionella</i> spp. | | Buffered Charcoal Yeast Extract (BCYE) | 1 | Broth (BHI broth) | | 3-5 days | 35 ± 2°C 5% CO ₂ | ⁵⁾ | ⁵⁾ | |
| <i>Pasteurella</i> spp. | | MHA + 5% blood (CLSI) MHF (EUCAST) | 1 | Broth (BHI broth) | | 48h | 35 ± 2°C 5% CO ₂ | ⁵⁾ | ⁵⁾ | |
| <i>Francisella tularensis</i> | | Cysteine Heart Agar + 10% blood ¹⁾ (or + 2% haemoglobin ³⁾) alternatively, Glucose Cysteine Blood Agar | 1 | Suspend 48h colonies from chocolate agar in broth (BHI broth) | Clindamycin (CM) Tetracycline (TC) Ciprofloxacin (CI) Gentamicin (GM) | 48-72h | 37 ± 2°C 5% CO ₂ | ⁵⁾ | ⁵⁾ | - Testing should only be performed in appropriate reference laboratories. - Perform all work within BSC Class IIA and minimum BSL 2 environment. |
| HACEK group | | MHA + 1% haemoglobin + 1% IsoVitalax or HTM or BBA | 1 | Broth (BHI broth) | Levofloxacin (LE) Imipenem (IP) Trimethoprim/sulfamethoxazole (TS) Ceftriaxone (TX) | 24-72h | 35 ± 2°C 5% CO ₂ | <i>H. influenzae</i> <i>H. influenzae</i> | 49247™ 49766™ (IP) | |

MYCOBACTERIA AND AEROBIC ACTINOMYCETES ¹⁾

| ORGANISM | SPECIFIC PHENOTYPE | MEDIA ⁶⁾ | INOCULUM | | SUGGESTED MIC PANEL ³⁾ | INCUBATION | | RECOMMENDED QUALITY CONTROL | | COMMENTS ⁴⁾ |
|-----------------------------------|--------------------|---|----------------------------------|---|---|----------------------------|--|---|-------------------------------------|--|
| | | | McF equivalent | Suspension medium | | Time (h) | Temperature/ Atmosphere | Strain | ATCC® | |
| <i>Mycobacterium tuberculosis</i> | | Middlebrook 7H11 + 10% OADC agar | 3-4 | M7H9 broth + 0.5% tween + 2% glycerol Vortex with sterile glass beads 3-5 mins, settle 20 mins & adjust supernatant to correct turbidity. | Ethambutol (EB) Ethionamide (ET) Isoniazide (IZ) Rifampicin (RI) | 5-10 days | 37 ± 2°C 5-10% CO ₂ | <i>Mycobacterium tuberculosis</i> <i>M. tuberculosis</i> | 27294™ AW388 (not ATCC) | - Pre-incubation 24h - 1 strip/90mm plate, seal plates - Perform all work within BSC class IIA |
| Nontuberculous mycobacteria | | MHA + 10% OADC + 5% blood (<i>M. kansasii</i> use same agar as for MTB) | 1 (3 for <i>M. kansasii</i>) | M7H9 broth Vortex with sterile glass beads 3-5 mins, settle 20 mins & adjust supernatant to correct turbidity. | Amikacin (AK) Ciprofloxacin (CI) Clarithromycin (CH) Rifampicin (RI) | 5-10 days | 35 ± 2°C (<i>M. marinum</i> at 30°C) 5% CO ₂ | <i>M. avium</i> <i>M. avium</i> spp. <i>avium</i> <i>M. marinum</i> <i>M. kansasii</i> | 700898™ 35713™ 927™ 12478™ | - 1 strip/90mm plate, seal plates - Antibiogram is species specific |
| Rapid growing mycobacteria | | MHA + 5% blood | 1 | Saline | Cefoxitin (FX) Imipenem (IP) Ciprofloxacin (CI) Clarithromycin (CH) | 48-72h | 30-35°C Ambient air, moist | <i>M. fortuitum</i> <i>M. peregrinum</i> | 6841™ 700686™ | - Subculture twice before preparing inoculum - 3-4 strips max./150mm plate to facilitate reading |
| <i>Nocardia</i> spp. | | MHA + 5% blood | 1 | Broth (BHI broth) | Amikacin (AK) Trimethoprim/sulfamethoxazole (TS) Ciprofloxacin (CI) Clarithromycin (CH) Imipenem (IP) | 48-72h (dependent on spp.) | 35 ± 2°C Ambient air | <i>S. aureus</i> | 29213™ | |

FUNGI

| ORGANISM | SPECIFIC PHENOTYPE | MEDIA ⁶⁾ | INOCULUM | | SUGGESTED MIC PANEL ³⁾ | INCUBATION | | RECOMMENDED QUALITY CONTROL | | COMMENTS ⁴⁾ |
|---------------------|--------------------|--|---|----------------------|---|---|--|--|------------------------------|--|
| | | | McF equivalent | Suspension medium | | Time (h) | Temperature/ Atmosphere | Strain | ATCC® | |
| Yeast | | RPMI 1640 + 2% glucose + MOPS + 1.5% Bacto agar | 0.5 (1 for <i>Cryptococcus neoformans</i>) | Saline | Fluconazole (FL) Itraconazole (IT) Amphotericin B (AP) ¹⁾ Flucytosine (FC) Voriconazole (VO) Caspofungin (CS) ¹⁾ | 24-48h. 48-72h for <i>C. neoformans</i> | 35 ± 2°C Ambient air in bags, moist | <i>Candida albicans</i> <i>C. krusei</i> <i>C. parapsilosis</i> | 90028™ 6258™ 22019™ | - Once plate inoculated, re-dip swab and streak again. |
| Mould ¹⁾ | | RPMI 1640 + 2% glucose + MOPS + 1.5% Bacto agar | 0.5 <i>Aspergillus</i> spp. (1 for <i>Fusarium</i> , <i>Rhizopus</i> spp.) | Saline + Tween 20 | Amphotericin B (AP) ¹⁾ Itraconazole (IT) Voriconazole (VO) ¹⁾ Posaconazole (POS) ¹⁾ Caspofungin (CS) ¹⁾ | 16-72h (Dependent on genus) | 35 ± 2°C Ambient air in bags, moist | <i>C. parapsilosis</i> <i>Aspergillus flavus</i> <i>A. fumigatus</i> | 22019™ 204304™ 204305™ | |

- 1) In the USA, For Research Use Only (RUO). The contents of this document do not in any way indicate or imply new *in vitro* diagnostic uses of Etest, outside those which are FDA-cleared for certain antibiotics and organism groups.
- 2) Worldwide, For Research Use Only (RUO).
- 3) Example based on CLSI®, Performance Standards for Antimicrobial Susceptibility Testing supplement M100-S. Please use your own selection of MIC panels.
- 4) Additional Etest information is available at www.biomerieux.com/techlib.
- 5) For QC of fastidious organisms, please refer to local recommendations and/or CLSI M45-A Methods for Antimicrobial Dilution and Disk Susceptibility Testing of Infrequently Isolated or Fastidious Bacteria.
- 6) For media available in the bioMérieux range, see page 10 (consult www.biomerieux.com/techlib for availability of certificates of compatibility).

KEY:

| | |
|-------------------|---|
| BORSA | Borderline ORSA (non-mec A resistance) due to type A macro-inducible β-lactamase inhibited by clavulanic acid |
| BSC | Biological Safety Cabinet |
| ESBL | Extended Spectrum β-Lactamase |
| HLAR | High-Level Aminoglycoside Resistance |
| MBL | Metallo β-Lactamase |
| MRCNS | Methicillin-Resistant Coagulase-Negative Staphylococci (mec A+) |
| MRSA | Methicillin-Resistant <i>Staphylococcus aureus</i> (mec A+) |
| ND | Non-Determinable |
| OADC | Oleic acid, Albumin, Dextrose Complex |
| PAP | Population Analysis Profile |
| VISA/hVISA | Vancomycin Intermediate/ hetero-Intermediate <i>Staphylococcus aureus</i> |

MEDIA AVAILABLE IN THE BIOMERIEUX RANGE

Consult the bioMérieux Technical Library (www.biomerieux.com/techlib) for availability of certificates of compatibility

| | |
|--|--|
| <p><u>For non-fastidious bacteria:</u></p> <ul style="list-style-type: none"> • Mueller Hinton 2 agar bioMérieux Ref. 43301/43309 - 20 / 100 plates 90 mm bioMérieux Ref. 43302 - 20 plates 145 mm bioMérieux Ref. 43511 - 20 plates 120 x 120 mm bioMérieux Ref. 41864 - 6 x 200 ml bioMérieux Ref. 51075 - 500 g | <p><u>For fastidious bacteria:</u> EUCAST recommendation:</p> <ul style="list-style-type: none"> • Mueller Hinton 2 horse blood NAD agar bioMérieux Ref. 43901/43919 - 20 / 100 plates 90 mm bioMérieux Ref. 43904 - 20 plates 120 x 120 mm <p>CLSI recommendation:</p> <ul style="list-style-type: none"> • Mueller Hinton 2 sheep blood agar bioMérieux Ref. 43321/43329 - 20 / 100 plates 90 mm bioMérieux Ref. 43324 - 20 plates 120 x 120 mm |
| <p><u>For anaerobes:</u></p> <ul style="list-style-type: none"> • Brucella blood agar (with Vitamin K1 + Hemin) bioMérieux Ref. 411 968 - 20 plates 90 mm | <p><u>For fungi and yeasts:</u></p> <ul style="list-style-type: none"> • RPMI agar bioMérieux Ref. AEB 122 180 - 10 plates 90 mm bioMérieux Ref. AEB 122 182 - 10 plates 140 mm |

SUSPENSION MEDIA AVAILABLE IN THE BIOMERIEUX RANGE

| | | |
|--|--|--|
| <ul style="list-style-type: none"> • Brain-Heart Infusion broth bioMérieux Ref. 42081 - 20 x 9 ml | <ul style="list-style-type: none"> • API® NaCl 0.85 % Medium (saline) bioMérieux Ref. 20070 – 100 x 2ml bioMérieux Ref. 20040 – 100 x 3ml bioMérieux Ref. 20230 – 100 x 5ml | <ul style="list-style-type: none"> • Schaedler Broth + vit. K3 bioMérieux Ref. 42106 - 20 x 13 ml |
|--|--|--|

BIOMERIEUX, the blue logo, API and Etest are used pending and/or registered trademarks belonging to bioMérieux, or one of its subsidiaries, or one of its companies.

CLSI is a registered trademark belonging to Clinical and Laboratory Standards Institute, Inc.

The ATCC trademark and trade name and any and all ATCC catalog numbers are trademarks of the American Type Culture Collection.

Any other name or trademark is the property of its respective owner.



 **bioMérieux SA**
Chemin de l'Orme
69280 Marcy-l'Etoile - France

RCS LYON 673 620 399
Tel. 33 (0)4 78 87 20 00
Fax 33 (0)4 78 87 20 90
www.biomerieux.com